A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings.

A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings. Abstract Text:

Mugdha Gore,Alesia Sadosky,Kei-Sing Tai,Brett Stacey,Mugdha Gore,Alesia Sadosky,Kei-Sing Tai,Brett Stacey,Mugdha Gore,Alesia Sadosky,Kei-Sing Tai,Brett Stacey,

BACKGROUND: Both gabapentin and pregabalin are approved for the management of postherpetic neuralgia (PHN), although dosing and pharmacokinetic differences between these medications may affect their use in actual practice. OBJECTIVES: This study was conducted to characterize the use of gabapentin and pregabalin in the management of PHN in clinical practice, with a specific focus on the doses actually prescribed and changes in the use of other neuropathic pain-related medications after the initiation of gabapentin or pregabalin. METHODS: The PharMetrics Patient-Centric Database was used to identify patients with PHN who were newly prescribed gabapentin or pregabalin between September 1, 2005, and March 31, 2006. The out-comes of interest were the prevalence of comorbidities, exposure to neuropathic pain-related medications (ie, the proportions of patients receiving >or=1 prescription for these medications in the 6-month periods before and after the date of the first gabapentin or pregabalin prescription), and attainment of therapeutic dose levels (gabapentin, >or=1800 mg/d; pregabalin, >or=150 mg/d). RESULTS: The database search identified 151 patients with PHN who were newly prescribed gabapentin (57.0% female; mean [SD] age, 55.8 [11.3] years) and 100 patients who were newly prescribed pregabalin (62.0% female; mean age, 52.8 [9.4] years). The prevalence of comorbidities did not differ significantly between recipients of prescriptions for gabapentin or pregabalin, with the exception of hyperlipidemia, which was more prevalent in those prescribed gabapentin (33.8% vs 22.0%, respectively; P = 0.044), and depression, which was more prevalent in those prescribed pregabalin (12.0% vs 4.6%, respectively; P = 0.031). In the pretreatment period, those who were prescribed pregabalin had significantly greater use of long-acting opioids (P = 0.005), anticonvulsants (P < 0.001), selective norepinephrine reuptake inhibitors (P < 0.001), and the lidocaine 5% patch (P = 0.005) compared with those prescribed gabapentin. Use of any opioid increased from pretreatment to follow-up in those prescribed gabapentin, significantly so in those who received >or=2 opioid prescriptions (P = 0.016). Use of any opioid decreased significantly from pre-treatment to follow-up in those prescribed pregabalin (P = 0.005), particularly in those who received >or=2 opioid prescriptions (P = 0.004). Tramadol use decreased significantly in those prescribed gabapentin (P = 0.045), and anticonvulsant use decreased significantly in those prescribed pregabalin (P = 0.004). Among patients prescribed gabapentin or pregabalin who received 1 prescription, 2 consecutive prescriptions, and >or=3 consecutive prescriptions, a greater proportion of those prescribed pregabalin attained therapeutic dose levels by their first, second, and third consecutive prescriptions compared with those prescribed gabapentin (69.0% vs 3.5%, respectively [P < 0.001]; 71.4% vs 21.7% [P < 0.001]; and 89.3% vs 46.2% [P < 0.001], respectively). CONCLUSIONS: In these patients with PHN in the usual-care setting, opioid use increased after the initiation of gabapentin and decreased after the initiation of pregabalin. Few of those prescribed gabapentin received a prescription for a therapeutic dose, whereas a greater proportion of patients who were prescribed pregabalin received a prescription for a therapeutic dose.

A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings. Publishing Authors By Initials

M Gore,A Sadosky,KS Tai,B Stacey,M Gore,A Sadosky,KS Tai,B Stacey,M Gore,A Sadosky,KS Tai,B Stacey,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Clinical therapeutics

VOLUME: 29

Page Numbers: 1655-70

Journal Abbreviation:

ISSN: 0149-2918

DAY: 8

MONTH: Aug

YEAR: 2007

A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7706726

A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings.

AFFILIATION: Avalon Health Solutions, inc., Philadelphia, Pennsylvania 19102, USA. mgore@avalonhealthsolutions.com

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Ther

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings Related Publications

• 51-year-old woman with double vision.
• A LysM Receptor-Like Kinase Plays a Critical Role in Chitin Signaling and Fungal Resistance in Arabidopsis.
• A lectin receptor-like kinase is required for pollen development in Arabidopsis.
• A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings.
• An oligonucleotide microarray resource for transcriptional profiling of Bradyrhizobium japonicum.
• Bacterial contamination of intraocular lens surgery.
• Brain amine concentrations after monoamine oxidase inhibitor administration.
• Changing medium and passaging cell lines.
• Concentrations of individual serum or plasma bile acids in workers exposed to chlorinated aliphatic hydrocarbons.
• DNA Motifs Suppressing TLR9 Responses.
• Exceeding PICU Goal With 0 VAP Cases.
• Fluorine and its compounds.
• Humoral effects of metastasising carcinoid tumours.
• INDUSTRIAL THERAPY; ONTARIO HOSPITAL, NEW TORONTO.
• Identification of 118 Arabidopsis transcription factor and 30 ubiquitin-ligase genes responding to chitin, a plant-defense elicitor.
• Improving nutrition.
• J. ERIC Stacey.
• JOHN Eric Stacey.
• Ligation of the adhesion-GPCR EMR2 regulates human neutrophil function.
• Maurice Stacey, C.B.E., 8 April 1907-9 October 1994.
• Realities for change in child health care: existing patterns and future possibilities.
• Role of third serum vitamin B 12 binding protein in vitamin B 12 transport.
• Sensory integration with chronic schizophrenics: a pilot study.
• Some physical properties of the specific polysaccharides from the types I, II, and III pneumococcus.
• Studies of the Bradyrhizobium japonicum nodD1 promoter: a repeated structure for the nod box.
• The Arabidopsis AtOPT3 Protein Functions in Metal Homeostasis and Movement of Iron to Developing Seeds.
• The constitution of a levan produced from sucrose by Pseudomonas mors-prunorum (Wormald).
• Toxic fluorine compounds containing the C-F link; methyl fluoroacetate and related compounds.
• Transcription Profiling of Soybean Nodulation by Bradyrhizobium japonicum.
• p27Kip1 and cyclin dependent kinase 2 regulate passage through the restriction point.